bitFlyer launches ‘Instant Buy’ to make buying cryptocurrency more accessible
5.12.2019 10:00:00 EET | Business Wire | Press release
Today, leading cryptocurrency exchange bitFlyer has announced the launch of Instant Buy on its Buy/Sell exchange platform in Europe. The feature, available on desktop and smartphone, allows users to buy cryptocurrency directly from bitFlyer, using credit card, debit card or local instant transfer methods such as Sofort, iDeal and GiroPay.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005083/en/
Instant Buy is now available with bitFlyer Buy/Sell (Photo: Business Wire)
Instant Buy is built for users looking for the fastest and simplest way to buy cryptocurrencies, as well as beginners looking for an all-in-one solution for purchasing, storing and securing their cryptocurrency investments.
Andy Bryant, Co-head and COO at bitFlyer Europe, said: “Instant Buy is the latest upgrade to bitFlyer’s Buy/Sell platform, as part of our goal to create a simpler, faster and transparent experience when it comes to buying virtual currencies. By making it similar to that of a traditional e-commerce experience, we are helping bringing cryptocurrency to a mainstream audience, while also giving experienced users a faster and simpler way to get their currency.”
This new feature, following bitFlyer’s recent app launch, is the latest development in a major growth strategy by the European side of the business in line with its vision to break down barriers to entry that many face while investing in cryptocurrency. Whilst the bitFlyer app has made it even easier for users to buy and sell from their smartphones, Instant Buy makes it more convenient for users to buy coins using their preferred payment method.
Other key features of Instant Buy include:
- Built for users looking for the fastest and simplest way to buy cryptocurrencies, as well as new adopters looking for an all-in-one solution to purchase, store and secure their investments
- Allows users to purchase cryptocurrencies (including the less mainstream altcoins such as Lisk, Monacoin and Ethereum Classic) directly from the bitFlyer platform at a predefined price, making the purchase experience significantly more straightforward
- Any fees related to payment processing are clearly displayed. bitFlyer does not charge additional fees on top of those that may be charged by payment service providers
bitFlyer launched in the USA in November 2017, followed by bitFlyer Europe in January 2018, both as fully owned subsidiaries of bitFlyer, Inc., a household name in the cryptocurrency space in Japan and one of the longest-standing cryptocurrency exchanges. It is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined and has also recently been recognised as one of only 10 exchanges that isn’t faking trading volumes.
ENDS
About bitFlyer EUROPE S.A.
bitFlyer EUROPE S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell virtual currencies. bitFlyer EUROPE S.A. site: https://bitflyer.com/en-eu/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005083/en/
Contact information
Lauren Armour
Tyto PR
+44(0)7826 557 326
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom